



Jersey

MISUSE OF DRUGS (MISCELLANEOUS AMENDMENTS) (JERSEY) ORDER 2010

Made

10th September 2010

Coming into force

17th September 2010

THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 3, 12, 13 and 27 of the Misuse of Drugs (Jersey) Law 1978¹, and after consultation with the Advisory Council on the Misuse of Drugs, orders as follows –

1 Schedule 2 to the Misuse of Drugs (Jersey) Law 1978 amended

- (1) In Part 2 of Schedule 2 to the Misuse of Drugs (Jersey) Law 1978² (the “Law”) –
 - (a) in paragraph 1(a) the words “Mephedrone (4-methylmethcathinone)” shall be deleted;
 - (b) in paragraphs 1(c), 1(d), 1(e) and 1(f), before the word “whether” where it last appears in each of those paragraphs there shall be inserted the word “and”;
 - (c) after paragraph 1(g) there shall be added the following sub-paragraphs –
 - “(h) any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a)) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say –
 - (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents,
 - (ii) by substitution at the 3-position with an alkyl substituent,

-
- (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
 - (i) any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say –
 - (i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents,
 - (ii) by substitution at the 3-position with an alkyl substituent,
 - (iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.”.
 - (2) In Part 3 of Schedule 2 to the Law paragraphs 1(d), (e) and (f) shall be deleted.

2 Misuse of Drugs (Designation) (Jersey) Order 1989 amended

- (1) In Part 1 of the Schedule to the Misuse of Drugs (Designation) (Jersey) Order 1989³ (the “1989 Order”), after paragraph 1(e) there shall be added the following sub-paragraphs –
 - “(f) any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a)) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say –
 - (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents,
 - (ii) by substitution at the 3-position with an alkyl substituent,
 - (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
 - (g) any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say –

- (i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents,
 - (ii) by substitution at the 3-position with an alkyl substituent,
 - (iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure;
- (h) 1-benzylpiperazine;
- (i) any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways –
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl substituents,
 - (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl substituents;
- (j) any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (k) any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (l) any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (m) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
- (n) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the

5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”.

- (2) In Part 2 of the Schedule to the 1989 Order, after paragraph 2 there shall be added the following paragraph –

“3 The compounds referred to in Part 1, paragraph 1(i) of this Schedule are –

1-(3-chlorophenyl)piperazine

1-(3-chlorophenyl)-4-(3-chlorophenyl)piperazine.”.

3 Misuse of Drugs (General Provisions) (Jersey) Order 2009 amended

In Schedule 1 to the Misuse of Drugs (General Provisions) (Jersey) Order 2009⁴ -

- (a) paragraphs 1(i), 1(j) and 1(k) shall be deleted;
- (b) in paragraphs 1(l), 1(m), 1(n) and 1(o), before the word “whether” where it last appears in each of those paragraphs there shall be inserted the word “and”;
- (c) after paragraph 1(p) there shall be added the following sub-paragraphs –

“(q) any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a)) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say –

- (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents,
- (ii) by substitution at the 3-position with an alkyl substituent,
- (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;

(r) any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say –

- (i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents,
- (ii) by substitution at the 3-position with an alkyl substituent,

-
- (iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.”.

4 Citation and commencement

This Order shall be cited as the Misuse of Drugs (Miscellaneous Amendments) (Jersey) Order 2010 and comes into force 7 days after it is made.

DEPUTY A.E. PRYKE OF TRINITY

Minister for Health and Social Services

-
- 1* chapter 08.680
 - 2* chapter 08.680
 - 3* chapter 08.680.40
 - 4* chapter 08.680.60